Classement en actions
#37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Prix de l'action
$0.07
Dernière synchronisation: 2024-11-12
Capitalisation boursière
$1.62M
Changement (1 jour)
0.00%
Échange Peak Bio, Inc. (PKBO)
Le prix PKBO avec la capitalisation boursière de B
Capitalisation boursière de Peak Bio, Inc.(PKBO)
Capitalisation boursière: $1.62M
En August 2026, Peak Bio, Inc. a une capitalisation boursière de $1.62M. Cela fait de Peak Bio, Inc. la 37553rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Peak Bio, Inc. du 2021 au 2026
PKBO par rapport au top 5 des plus populaires stocks
| Prix pour PKBO |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+336,854,984.03%
|
|
|
|
|
$4.490T
|
+277,425,214.66%
|
|
|
|
|
$4.162T
|
+257,182,948.93%
|
|
|
|
|
$3.676T
|
+227,150,429.30%
|
|
|
|
|
$2.833T
|
+175,045,381.37%
|
